All Stories

  1. Prevention of M2 polarization and temporal limitation of differentiation in monocytes by extracellular ATP
  2. Response
  3. Analysis of single nucleotide polymorphisms in chronic beryllium disease
  4. Insights into immunometabolism: A dataset correlating the 18FDG PET/CT maximum standard uptake value of the primary tumor with the CCL18 serum level in non-small cell lung cancer
  5. A Cluster of Beryllium Sensitization Traced to the Presence of Beryllium in Concrete Dust
  6. Bronchoalveolar Lavage Fluid Reflects a TH1-CD21low B-Cell Interaction in CVID-Related Interstitial Lung Disease
  7. Surveillance Bronchoscopy for the Care of Lung Transplant Recipients: A Retrospective Single Center Analysis
  8. Safety and efficacy of abatacept in patients with treatment-resistant SARCoidosis (ABASARC) – protocol for a multi-center, single-arm phase IIa trial
  9. Vasoactive Intestinal Peptide in Checkpoint Inhibitor–Induced Pneumonitis
  10. Interaction Between CCL18 and GPR30 Differs from the Interaction Between Estradiol and GPR30
  11. The value of bronchoalveolar lavage for discrimination between healthy and diseased individuals
  12. Kinetics of Torque Teno Virus-DNA Plasma Load Predict Rejection in Lung Transplant Recipients
  13. Bronchoalveolar lavage in healthy and diseased individuals
  14. Human alveolar epithelial cells type II are capable of TGFβ-dependent epithelial-mesenchymal-transition and collagen-synthesis
  15. AtopobiumandFusobacteriumas novel candidates for sarcoidosis-associated microbiota
  16. Is serum level of CC chemokine ligand 18 a biomarker for the prediction of radiation induced lung toxicity (RILT)?
  17. P2Y6 Receptor Activation Promotes Inflammation and Tissue Remodeling in Pulmonary Fibrosis
  18. Sarcoidosis: Drugs under Investigation
  19. The purinergic receptor subtype P2Y2 mediates chemotaxis of neutrophils and fibroblasts in fibrotic lung disease
  20. Turning back the Wheel: Inducing Mesenchymal to Epithelial Transition via Wilms Tumor 1 Knockdown in Human Mesothelioma Cell Lines to Influence Proliferation, Invasiveness, and Chemotaxis
  21. Functional Toll-Like Receptor 9 Expression and CXCR3 Ligand Release in Pulmonary Sarcoidosis
  22. Association Study for 26 Candidate Loci in Idiopathic Pulmonary Fibrosis Patients from Four European Populations
  23. Sarcoidosis: Pathogenesis and Epidemiology . . . . . . . . . . . . . Gernot Zissel, Antje Prasse, and Joachim M€uller-Quernheim
  24. Neue pathogenetische Konzepte und frühe pharmakologische Studien bei der Sarkoidose
  25. Specific antigen(s) in sarcoidosis: a link to autoimmunity?
  26. Altered purinergic signaling in the tumor associated immunologic microenvironment in metastasized non-small-cell lung cancer
  27. Chronische Berylliose
  28. Uridine supplementation exerts anti-inflammatory and anti-fibrotic effects in an animal model of pulmonary fibrosis
  29. Genetik der Sarkoidose
  30. Are bronchoalveolar lavages a good source for microbial profiling? Differences between throat and bronchoalveolar lavage microbiomes
  31. Macrophage Activation in Acute Exacerbation of Idiopathic Pulmonary Fibrosis
  32. The chemokine CCL18 characterises Pseudomonas infections in cystic fibrosis lung disease
  33. Cellular Activation in the Immune Response of Sarcoidosis
  34. mRNA and miRNA analyses in cytologically positive endobronchial ultrasound-guided transbronchial needle aspiration: Implications for molecular staging in lung cancer patients
  35. Lung Collagens Perpetuate Pulmonary Fibrosis via CD204 and M2 Macrophage Activation
  36. Genetisches Risikoprofil der Sarkoidose
  37. Sarcoidosis
  38. Sarcoidosis
  39. Soluble CD90 as a potential marker of pulmonary involvement in systemic sclerosis
  40. CC-Chemokine Ligand 18 Induces Epithelial to Mesenchymal Transition in Lung Cancer A549 Cells and Elevates the Invasive Potential
  41. Genetics
  42. Effect of CCL18 on Epithelial-Mesenchymal Transition (EMT) of alveolar epithelial cells
  43. Influence of Phosphodiesterase-Inhibitor PDE4 Roflumilast N-Oxide on Surfactant Protein of human Alveolar Epithelial Cell Type II
  44. CC-Chemokine Ligand 18 Induces Epithelial to Mesenchymal Transition in Lung Cancer A549 Cells and Enhances Metastatic Potential
  45. Chemotaxis and Transcription Factor Activation of Wild-Type and CCR6-Transfected RLE-6TN
  46. Alternative screening assay to beryllium lymphocyte proliferation test for identification of beryllium sensitization – Pilot study
  47. Differenzial analysis of antioxidative capacities in the alveolar compartment of diffuse parenchymal lung disorders and diseased controls
  48. Characterization of the lung microbiome in sarcoidosis and healthy individuals with respect to host genotype
  49. A Novel Sarcoidosis Risk Locus for Europeans on Chromosome 11q13.1
  50. Genome-wide association analysis reveals 12q13.3–q14.1 as new risk locus for sarcoidosis
  51. Serum Level of CC-Chemokine Ligand 18 Is Increased in Patients with Non-Small-Cell Lung Cancer and Correlates with Survival Time in Adenocarcinomas
  52. Roflumilast-N-oxide Induces Surfactant Protein Expression in Human Alveolar Epithelial Cells Type II
  53. Pathogenesis of sarcoidosis
  54. CCL18 -- Potential Biomarker of Fibroinflammatory Activity in Chronic Periaortitis
  55. Serum Level Of CC-Chemokine Ligand 18 Is Increased In Patients With Non Small Cell Lung Cancer And Correlates With Survival Time In Adenocarcinoma
  56. Differential Cell Counts Of Bronchoalveolar Lavage In 250 Healthy Volunteers
  57. Tumor-Cell Co-Culture Induced Alternative Activation of Macrophages Is Modulated by Interferons In Vitro
  58. Autorinnen und Autoren
  59. Die Serumkonzentration des CC Chemokin ligand 18 (CCL18) ist bei Patienten mit NCCLC erhöht und korreliert mit der Überlebenszeit
  60. CC Chemokin ligand 18 (CCL18) induziert Chemotaxis, EMT und Chemo-Resistance bei der Lungenkarzinomzelllinie A549
  61. Generation and evaluation of a monoclonal antibody, designated MAdL, as a new specific marker for adenocarcinomas of the lung
  62. Purinergic Receptor Type 6 Contributes to Airway Inflammation and Remodeling in Experimental Allergic Airway Inflammation
  63. Identification Of The CCL18 Receptor - Effects Of CCL18 On Human Lung Fibroblasts In Pulmonary Fibrosis Are Mediated Via CCR6
  64. P2X7Receptor Signaling in the Pathogenesis of Smoke-Induced Lung Inflammation and Emphysema
  65. Alternatively activated alveolar macrophages in pulmonary fibrosis—mediator production and intracellular signal transduction
  66. Inhaled Vasoactive Intestinal Peptide Exerts Immunoregulatory Effects in Sarcoidosis
  67. Immunologic Response of Sarcoidosis
  68. Purinergic Receptor Inhibition Prevents the Development of Smoke-Induced Lung Injury and Emphysema
  69. Peripheral Mucosa-homing T Cells In Fibrosis Patients Preferentially Release Th2 Cytokines
  70. Extracellular Adenosine Triphosphate and Chronic Obstructive Pulmonary Disease
  71. M2 Marker Expression By Alveolar Macrophages Predicts Survival In IPF
  72. Local administration of uridine suppresses the cardinal features of asthmatic airway inflammation
  73. Nachweis einer spezifischen T-Zellantwort gegenüber myko- und propionibakteriellen Antigene bei Sarkoidosepatienten
  74. Essential Role of Osteopontin in Smoking-Related Interstitial Lung Diseases
  75. Serum CC-Chemokine Ligand 18 Concentration Predicts Outcome in Idiopathic Pulmonary Fibrosis
  76. CCL18 Production is Decreased in Alveolar Macrophages from Cigarette Smokers
  77. Pulmonary Regulatory T-Cell Counts Correlate with Disease Activity in Patients with Sarcoidosis.
  78. Arginase and NOS2 Are Involved in the Regulation of CCL18 Release.
  79. Influence of CCL18 on Epithelial-to-Mesanchial Transdifferentiation of Epithelial Cells.
  80. CCL18 and IP10 Probe Tumor Cell-Induced Monocyte Differenciation.
  81. Nachweis einer spezifischen T-Zellantwort gegenüber myko- und propionibakteriellen Antigene bei Sarkoidosepatienten
  82. Einfluss von anorganischem Feinstaub auf Epithelzellen und Monozyten
  83. Propionibakterium-Lysat induzierte inflammatorische Lungenveränderungen in Abhängigkeit vom genetischem Hintergrund
  84. Einfluss von CCL18 auf die Epithelial-to-Mesanchial Transdifferentiation (EMT) von Alveolarepithelzellen
  85. CCL18 und IP10 als Marker für Monozytendifferenzierung in Kokultur mit A549 bei Stimulation mit Interferon α, β oder γ
  86. Nekrose und Apoptose humaner Alveolarepithelzellen Typ II nach biaxialer Dehnung
  87. Differences in form stability between human non-tumorous alveolar epithelial cells type 2 and alveolar carcinoma cells under biaxial stretching
  88. Genetik der Sarkoidose: Ein Schlüssel zum Verständnis ihrer Pathogenese
  89. The Hidden Macrophage
  90. Inflammatory markers in exhaled breath condensate following lung resection for bronchial carcinoma
  91. Genetics of Sarcoidosis
  92. Activation of Human Alveolar Macrophages via P2 Receptors: Coupling to Intracellular Ca2+ Increases and Cytokine Secretion
  93. Interleukin-13 acts as an apoptotic effector on lung epithelial cells and induces pro-fibrotic gene expression in lung fibroblasts
  94. Phenotyping Sarcoidosis from a Pulmonary Perspective
  95. Diagnoses of chronic beryllium disease within cohorts of sarcoidosis patients
  96. Polymorphismen im ACE- und Angiotensin Rezeptor AT2R1 Gen determinieren den Serum-ACE Spiegel bei Patienten mit Sarkoidose
  97. Expression und Bedeutung des TLR9 auf BAL Zellen von Patienten mit Sarkoidose und EAA
  98. Serum CCL18 Konzentrationen haben einen prognostischen Wert bei der Idiopathischen Lungenfibrose
  99. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis
  100. CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis
  101. Sarcoidosis-Immunopathogenetic Concepts
  102. IL-10–producing monocytes differentiate to alternatively activated macrophages and are increased in atopic patients
  103. Chronische Berylliose
  104. Serotoninergic Receptors on Human Airway Epithelial Cells
  105. Expression und Bedeutung des TLR9 auf BAL Zellen von Patienten mit Sarkoidose und EAA
  106. Genotype-corrected reference values for serum angiotensin-converting enzyme
  107. Functional characterization of histamine receptor subtypes in a human bronchial epithelial cell line
  108. Chemokines Indicate Allergic Bronchopulmonary Aspergillosis in Patients with Cystic Fibrosis
  109. Diagnoses of chronic beryllium disease within cohorts of sarcoidosis patients
  110. A Vicious Circle of Alveolar Macrophages and Fibroblasts Perpetuates Pulmonary Fibrosis via CCL18
  111. Interleukin-18 expression by alveolar epithelial cells type II in tuberculosis and sarcoidosis
  112. Pulmonary TH2 response in Pseudomonas aeruginosa–infected patients with cystic fibrosis
  113. Antigen-Presenting Cells in Sarcoidosis
  114. The P2Y14 Receptor of Airway Epithelial Cells
  115. A role for MCP-1/CCR2 in interstitial lung disease in children
  116. CCR2 and CXCR3 agonistic chemokines are differently expressed and regulated in human alveolar epithelial cells type II
  117. Pulmonary chemokines and their receptors differentiate children with asthma and chronic cough
  118. Monocyte chemoattractant protein MCP-1 gene polymorphism in Sarcoidosis
  119. The Serotoninergic Receptors of Human Dendritic Cells: Identification and Coupling to Cytokine Release
  120. Alveolar macrophages are the main source for tumour necrosis factor‐α in patients with sarcoidosis
  121. Systemic Immune Cell Activation in a Subgroup of Patients with Idiopathic Pulmonary Fibrosis
  122. HOPE-Fixation Enables Improved PCR-Based Detection and Differentiation of Mycobacterium tuberculosis Complex in Paraffin-Embedded Tissues
  123. Prostaglandin E2 reinforces the activation of Ras signal pathway in lung adenocarcinoma cells via EP3
  124. Human alveolar epithelial cells induce nitric oxide synthase‐2 expression in alveolar macrophages
  125. Assessment of Transcriptional Gene Activity in situ by Application of HOPE-fixed, Paraffin-embedded Tissues
  126. Redox states of type 1 ryanodine receptor alter Ca 2+ release channel response to modulators
  127. Formation of Granulomas in the Lungs of Severe Combined Immunodeficient Mice after Infection with Bacillus Calmette-Guerin
  128. Accessory Function and Costimulatory Molecule Expression of Alveolar Macrophages in Patients with Pulmonary Tuberculosis
  129. Pharmacological modulation of the IFNγ-induced accessory function of alveolar macrophages and peripheral blood monocytes
  130. POLYMORPHISMS AT POSITION −308 IN THE PROMOTER REGION OF THE TNF-α AND IN THE FIRST INTRON OF THE TNF-β GENES AND SPONTANEOUS AND LIPOPOLYSACCHARIDE-INDUCED TNF-α RELEASE IN SARCOIDOSIS
  131. Analysis of the Kveim-Siltzbach Test Reagent for Bacterial DNA
  132. Serum Level of Interleukin 8 Is Elevated in Idiopathic Pulmonary Fibrosis and Indicates Disease Activity
  133. Sarcoidosis: historical perspective and immunopathogenesis (part I)
  134. Sarcoidosis: TNF- α Release from Alveolar Macrophages and Serum Level of sIL-2R Are Prognostic Markers
  135. TCR V β Families in T Cell Clones from Sarcoid Lung Parenchyma, BAL, and Blood
  136. Anti-<I>Borrelia burgdorferi</I> immunoglobulin seroprevalence in pulmonary sarcoidosis: a negative report
  137. Shed soluble ICAM-1 molecules in bronchoalveolar lavage cell supernatants and serum of patients with pulmonary sarcoidosis
  138. Th1/Th2 cell distribution in pulmonary sarcoidosis.
  139. Anti-inflammatory cytokine release by alveolar macrophages in pulmonary sarcoidosis.
  140. Spontaneous interleukin 2 release of bronchoalveolar lavage cells in sarcoidosis is a codeterminator of prognosis
  141. Induction of accessory cell function of human alveolar macrophages by inhalation of human natural interleukin-2
  142. Differentialdiagnose Berylliose/Sarkoidose bei einem Zahntechniker
  143. Value of bronchoalveolar lavage in the differential diagnosis of interstitial lung disease